Reta 15mg Retatrutide is a GGG tri-agonist that targets GLP-1 and GIP receptors, akin to standard GLP-1 agonists, but also uniquely activates the glucagon receptor. This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists.

Clinical Data:

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)

Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial

Disclaimer:
This product is not intended for human or animal consumption. It is exclusively designed for research by qualified professionals. Any potential therapeutic applications should undergo rigorous exploration, validation, and further research, including clinical trials.